This preprint is under consideration at Supportive Care in Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
shahin nargesi
Iran University of Medical Sciences
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Cancer imposes a significant economic burden on the health system and society. Acute myeloid leukemia (AML) is the third deadliest leukemia and is one of the leading health problems worldwide. The present study aims to estimate the economic burden of AML in Iran for 2020.
Methods
In this study, we estimated a prevalence-based on the cost-of-illness of the AML in Iran. A societal perspective was considered, in which the direct costs and productivity losses with the adoption of the human capital approach in the AML cases were estimated for 2020. Moreover, in the present study, several resources including national cancer registry reports, hospital records, occupational data, and interviews with experts were cited.
Result
Approximately 98% of patients with AML received induction therapy. The AML economic burden was $ 33243107.39. Indirect costs accounted for 60% of this amount, and direct medical costs made up for 19% of this estimated economic burden.
Conclusion
The economic burden of AML in Iran is very significant and due to the increasing prevalence of this disease, it is expected to increase more gradually. Awareness of the costs associated with this disease provides a great opportunity for policymakers and managers of the health systems to improve resource allocation efficiently.
Keywords
Acute myeloid leukemia, consolidation therapy, Iran, induction therapy, economic burden, cost-of-illness
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 19 Mar, 2021
No community comments so far
Review #? received
Received 16 Mar, 2021
Editor invited
On 16 Mar, 2021
Reviewers invited
Invitations sent on 16 Mar, 2021
Editor assigned
On 22 Feb, 2021
First submitted
On 12 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Health Economics & Outcomes Research
Learn more about our company.
This preprint is under consideration at Supportive Care in Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
shahin nargesi
Iran University of Medical Sciences
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 19 Mar, 2021
No community comments so far
Review #? received
Received 16 Mar, 2021
Editor invited
On 16 Mar, 2021
Reviewers invited
Invitations sent on 16 Mar, 2021
Editor assigned
On 22 Feb, 2021
First submitted
On 12 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Health Economics & Outcomes Research
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Cancer imposes a significant economic burden on the health system and society. Acute myeloid leukemia (AML) is the third deadliest leukemia and is one of the leading health problems worldwide. The present study aims to estimate the economic burden of AML in Iran for 2020.
Methods
In this study, we estimated a prevalence-based on the cost-of-illness of the AML in Iran. A societal perspective was considered, in which the direct costs and productivity losses with the adoption of the human capital approach in the AML cases were estimated for 2020. Moreover, in the present study, several resources including national cancer registry reports, hospital records, occupational data, and interviews with experts were cited.
Result
Approximately 98% of patients with AML received induction therapy. The AML economic burden was $ 33243107.39. Indirect costs accounted for 60% of this amount, and direct medical costs made up for 19% of this estimated economic burden.
Conclusion
The economic burden of AML in Iran is very significant and due to the increasing prevalence of this disease, it is expected to increase more gradually. Awareness of the costs associated with this disease provides a great opportunity for policymakers and managers of the health systems to improve resource allocation efficiently.
Figure 1
Loading...